Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Future directions for the treatment of diffuse large B-cell lymphoma

Christian Gisselbrecht • 12 Jun 2015
EHA 2015
Diffuse Large B-Cell Lymphoma Ibrutinib Lenalidomide

At the 20th Congress of the European Hematology Association (EHA), Christian Gisselbrecht, MD, of Paris Diderot University, Paris, France, highlights the unmet clinical needs and emerging therapeutic options for patients with diffuse large B-cell lymphoma (DLBCL). Research is moving towards targeted agents that utilize the improved understanding of disease biology in patient subgroups with the poorest prognoses.

More from Christian Gisselbrecht

Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
The current status of autologous transplantation in PTCL
1:15
The current status of autologous transplantation in PTCL
Christian Gisselbrecht • 25 Apr 2023
LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT
2:11
LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT
Christian Gisselbrecht • 31 Aug 2020

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
2:17
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
Michael Jain • 11 Sep 2026
Optimizing post-CAR-T monitoring and community delivery after liso-cel
1:04
Optimizing post-CAR-T monitoring and community delivery after liso-cel
Bradley Hunter • 21 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals